Publications by authors named "M P Needham"
Background: Several health care networks have fully adopted second-generation supraglottic airway (SGA) i-gel. Real-world evidence of enhanced patient safety after such practice change is lacking. We hypothesized that the implementation of i-gel compared to the previous LMA®-Unique™ would be associated with a lower risk of airway-related safety events.
View Article and Find Full Text PDFInclusion body myositis (IBM) is an inflammatory myopathy, characterised by slow progression of weakness, skeletal muscle atrophy, and heterogeneous clinical presentation. This variability in disease progression and presentation complicates tracking of clinical progress and intervention response in clinical trials, presenting challenges in identifying reliable outcome measures. We aimed to identify the most useful suite of clinician-assessed and patient-reported outcome measures (PROMs) for use in clinical practice and trials from a selection of the most commonly used outcome measures in IBM.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates CP symmetry violation in the decay of D^{+} particles into K^{-}K^{+}π^{+} using data from proton-proton collisions at a high energy of 13 TeV.
- A unique model-independent method was employed to analyze the phase-space distributions of D^{+} and D^{-} particles, correcting for any instrumental biases using D_{s}^{+} decays.
- The findings indicate no significant evidence of CP violation, with a p value of 8.1%, and measure specific CP asymmetry observables, marking this study as the most sensitive search of its kind in multibody decays.
Article Synopsis
- IIMs are autoimmune diseases that lead to muscle inflammation and have serious health impacts, but due to their rarity and variability, understanding these conditions has been difficult.
- The Australian Myositis Registry (AMR) is a new national database that collects clinical and patient data from IIM patients in Australia to enhance research and improve outcomes.
- Launched in 2023 with 170 participants so far, the AMR aims to expand its reach and is significant as Australia’s first national registry for IIMs, providing crucial data for understanding the diseases' epidemiology and improving patient care.
In 2022, the U.S. Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), U.
View Article and Find Full Text PDF